Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

Also called NCT01234597

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 219 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01234597
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Israel (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01234597. Randomized; no masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2015-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Acronym
SeLan
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE (HOE901)
Intervention (Drug)
INSULIN GLULISINE (HMR1964)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01234597
Content hash
523c804cf071fe96d88f50aee04330c50ec2d65b9d34f483858c5c9686d6ae64